Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PER2 | O15055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24263535 | 0.98 | TSHR (0.89) | TSHRKMT2AL3MBTL1HTTBLM | |
| Piracetam SCHEMBL20172 | 0.92 | TSHR (1.00) | TSHRKMT2AHTTBLMAPEX1 | |
| Piracetam SCHEMBL6140872 | 0.92 | TSHR (1.00) | TSHRKMT2AHTTBLMAPEX1 | |
| Piracetam SCHEMBL28423013 | 0.90 | TSHR (0.96) | TSHRKMT2AHTTBLMAPEX1 | |
| SCHEMBL8552055 | 0.84 | — | — | |
| SCHEMBL11036951 | 0.82 | TSHR (0.58) | TSHRKMT2AL3MBTL1HTTBLM | |
| SCHEMBL596327 | 0.82 | TSHR (0.58) | TSHRKMT2AL3MBTL1HTTBLM | |
| SCHEMBL9821183 | 0.82 | TSHR (0.58) | TSHRKMT2AL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL1520530 | 0.81 | TSHR (0.58) | TSHRKMT2AL3MBTL1BLMPIK3CD | |
| SCHEMBL12554864 | 0.81 | TSHR (0.56) | TSHRKMT2AL3MBTL1HTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901752-A4 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | NOVARTIS AG (CH) | 2009-07-08 | — | — | EP | claimed |
| US-20090042858-A1 | LACTAM CONTAINING HCV INHIBITORS | BARSANTI PAUL | 2009-02-12 | — | — | US | claimed |
| EP-1901752-A2 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2007120160-A2 | LACTAM CONTAINING HCV INHIBITORS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | claimed |
| EP-4263526-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | Pfizer Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022130171-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | PFIZER INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-2293670-B1 | COMPOSITIONS AND METHODS FOR NAIL FUNGUS TREATMENT | ARCH CHEM INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2293670-A1 | COMPOSITIONS AND METHODS FOR NAIL FUNGUS TREATMENT | Arch Chemicals, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010144293-A1 | SYNTHESIS OF TELCAGEPANT AND INTERMEDIATES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2009148794-A1 | COMPOSITIONS AND METHODS FOR NAIL FUNGUS TREATMENT | ARCH CHEMICALS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090298805-A1 | TOPICAL PYRITHIONE COMPOSITIONS AND METHODS FOR TREATMENT OF NAIL FUNGUS | ARCH CHEMICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| CN-101511352-A | Lactam containing HCV inhibitors | NOVARTIS AG (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-1901752-A4 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | NOVARTIS AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20090042858-A1 | LACTAM CONTAINING HCV INHIBITORS | BARSANTI PAUL | 2009-02-12 | — | — | US | disclosed |
| US-20090042858-A1 | LACTAM CONTAINING HCV INHIBITORS | BARSANTI PAUL | 2009-02-12 | — | — | US | disclosed |
| WO-2007120160-A3 | LACTAM CONTAINING HCV INHIBITORS | NOVARTIS AG (CH) | 2008-12-04 | — | — | WO | disclosed |
| EP-1901752-A2 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| EP-1901752-A2 | COMPOSITIONS AND METHODS FOR VIRAL INHIBITION | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007120160-A2 | LACTAM CONTAINING HCV INHIBITORS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120160-A2 | LACTAM CONTAINING HCV INHIBITORS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042858-A1 | LACTAM CONTAINING HCV INHIBITORS | SARS1, ZC3HAV1, ACE2 | TSHR 4838/4885KMT2A 3230/4885L3MBTL1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.